PDF herunterladen
Semin Thromb Hemost 1995; 21(S 04): 063-071
DOI: 10.1055/s-0032-1313624
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thromboelastographic Study of Fibrinolytic Agents

Louis Summaria
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
09. Mai 2012 (online)

  als PDF herunterladen  Lizenzen und Reprints
 

  • References

  • 1 Fletcher AP, Alkaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 71: 287-296 1958;
    PubMedGoogle Scholar
  • 2 Hansen PF, Jorgensen M, Kjeldgaard NO, Ploug J. Urokinase—an activator of plasminogen from human urine. Experiences with intravenous application on twenty-two patients. Angiology 12: 367-371 1961;
    CrossrefPubMedGoogle Scholar
  • 3 Fletcher AP, Alkaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 65: 713-731 1965;
    PubMedGoogle Scholar
  • 4 Urokinase-streptokinase pulmonary embolism trials. JAMA 229: 1606-1626 1974;
    CrossrefPubMed
  • 5 White WF, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 5: 2160-2169 1966;
    CrossrefPubMedGoogle Scholar
  • 6 European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction: Streptokinase in acute myocardial infarction. N Engl J Med 301: 779-785 1979;
    CrossrefPubMed
  • 7 Summaria L, Arzadon L, Bernabe P, Robbins KC. The interactions of streptokinase with human, cat, dog and rabbit plasminogens. The fragmentation of streptokinase in the equimolar plasminogenstreptokinase complex. J Biol Chem 249: 4760-4769 1974;
    PubMedGoogle Scholar
  • 8 Marder VJ. Guidelines for thrombolytic therapy of deep-vein thrombosis. Prog Cardiovasc Dis 21: 327-332 1979;
    CrossrefPubMedGoogle Scholar
  • 9 Bell WR, Meek AG. Guidelines for the use of thrombolytic agents. N Engl J Med 301: 1266-1270 1979;
    CrossrefPubMedGoogle Scholar
  • 10 Sherry S. History and development of thrombolytic therapythrombolytic therapy. In: Camerota AJ, (Ed) Thrombolytic Therapy. Grune & Stratton; New York: 1988
    Google Scholar
  • 11 Rentrop KP, Blanke H, Karsch KR. Acute myocardial infarction: Intracoronary application of nitroglycerine and streptokinase in combination with transluminal recanalization. Clin Cardiol 2: 354-363 1979;
    PubMedGoogle Scholar
  • 12 Ganz W, Buchbinder N, Marcus H, Mondkar A. Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J 101: 4-13 1981;
    CrossrefPubMedGoogle Scholar
  • 13 Mathey DG, Kuck KH, Tilsner V, Krebber HI, Bleifield W. Nonsurgical coronary artery recanalization in acute transmural myocardial infarction. Circulation 63: 489-497 1981;
    CrossrefPubMedGoogle Scholar
  • 14 Markis JE, Molagold M, Parker A, Silverman KJ. Myocardial salvage after intracoronary thrombolysis with streptokinase in acute myocardial infarction. N Engl J Med 305: 77-82 1981;
    CrossrefPubMedGoogle Scholar
  • 15 Sheehan FH, Mathey DG, Schofer J, Krebber HI, Dodge HT. Effect of interventions in salvaging left ventricular function in acute myocardial infarction: A study of intracoronary streptokinase. Am J Cardiol 52: 431-438 1983;
    CrossrefPubMedGoogle Scholar
  • 16 Bergman SR, Lerch RA, Fox KAA. Temporal dependence of beneficial effects of coronary thrombolysis characterized by position tomography. Am J Med 73: 573-581 1982;
    CrossrefPubMedGoogle Scholar
  • 17 Kennedy JW, Ritchie JL, Davis KB, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 309: 1477-1482 1983;
    CrossrefPubMedGoogle Scholar
  • 18 Collen D, Rijken DC, Van Damme J, Billiau A. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo. Thromb Haemostas 48: 294-296 1982;
    PubMedGoogle Scholar
  • 19 Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 291: 590-598 1981;
    CrossrefPubMedGoogle Scholar
  • 20 Kominger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 69: 573-580 1982;
    CrossrefPubMedGoogle Scholar
  • 21 Collen D, Topol EJ, Tiefenbrun AJ. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective, randomized placebo-controlled trial. Circulation 70: 1012-1017 1984;
    CrossrefPubMedGoogle Scholar
  • 22 Van de Werf F, Ludbrook PA, Bergman SR, Tiefenbrunn AJ, Fox KAA, de Geest H, Verstraete M, Collen D, Sohel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 310: 609-613 1984;
    CrossrefPubMedGoogle Scholar
  • 23 Dupe RJ, English PD, Smith RAG, Green J. The activity of an acylated streptokinase-plasminogen complex (BRL 26921) in dog models of thrombosis. In: Davidson IF, Bachmann F, Bouvier CA, Kruithof EK, (Eds.) Progress in Fibrinolysis. Churchill Livingstone; Edinburgh: 1983
    Google Scholar
  • 24 Walker JD, Davidson IF, Rae AP, Hutton I, Lawrie TDV. Acylated streptokinase-plasminogen complex in patients with acute myocardial infarction. Thromb Haemostas 51: 204-206 1984;
    PubMedGoogle Scholar
  • 25 Summaria L, Robbins KC. Isolation of a human plasmin-derived functionally active,light (B) chain capable offorming with streptokinase an equimolar light (B) chain-streptokinase complex with plasminogen activator activity. J Biol Chem 251: 5810-5813 1976;
    PubMedGoogle Scholar
  • 26 Wohl RC, Summaria L, Robbins KC. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37°C. J Biol Chem 255: 2005-2013 1980;
    PubMedGoogle Scholar
  • 27 Wohl RC, Summaria L, Arzadon L, Robbins KC. Steady state kinetics of activation of human and bovine plasminogens by streptokinase and its equimolar complexes with various activated forms of human plasminogen. J Biol Chem 253: 1402-1407 1978;
    PubMedGoogle Scholar
  • 28 Robbins KC, Wohl RC, Summaria L. Activation of human plasminogen in both purified systems and plasma by streptokinase and urokinase activator species. In: Davidson JF, Cepelak V, Samama MM, Desnoyers PC, (Eds.) Progress in Chemical Fibrinolysis and Thrombolysis. IV. Churchill Livingstone; Edinburgh: 1979: 330-338
    Google Scholar
  • 29 Summaria L, Boreisha IG, Arzadon L, Robbins KC. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain. Thromb Res 11: 377-389 1977;
    CrossrefPubMedGoogle Scholar
  • 30 Summaria L. The plasmin B-chain-streptokinase complex. In: Camerota AJ, (Ed.) Thrombolytic Therapy. Grune & Stratton; New York: 1988
    Google Scholar
  • 31 Gurewich V. Tissue plasminogen activator and pro-urokinase. In: Camerota AJ, (Ed.) Thrombolytic Therapy. Grune & Stratton; New York: 1988
    Google Scholar
  • 32 Gurewich V, Pannell R. Fibrin-specificity and efficacy of proteolysis induced by single chain urokinase (SC-UK) in plasma. Thromb Haemostas 50: 1018-1025 1983;
    PubMedGoogle Scholar
  • 33 Van de Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Ann Intern Med 104: 345-351 1986;
    PubMedGoogle Scholar
  • 34 Martin M. Streptokinase in Chronic Arterial Disease. CRC Press; Boca Raton, FL: 1982
    Google Scholar
  • 35 Summaria L, Sandesara J, Yang G, Vagher JP, Caprini JA. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method; in vivo evaluation of the B-chainstreptokinase complex in the dog model using pre-titered doses. Thromb Haemostas 56: 71-79 1986;
    PubMedGoogle Scholar
  • 36 Summaria L, Arzadon L, Bernabe P, Robbins KC, Barlow GH. Characterization of the amino terminal glutamic acid and the amino terminal lysine forms of human plasminogen isolated by affinity chromatography and isoelectric focusing methods. J Biol Chem 248: 2984-2991 1973;
    PubMedGoogle Scholar
  • 37 Haverkate F, Traas DW. Dose-response curves in the fibrin plate assay. Fibrinolytic activity of proteases. Thromb Diathes Haemorrh 32: 356-365 1974;
    PubMedGoogle Scholar
  • 38 Rothbard RL, Fitzpatrick PG, Caton DM, Francis CW, Hood Jr WB, Marder VJ. Relationship of systemic lytic state to acute thrombolysis with standard dose and low-dose intracoronary streptokinase. Circulation 67 (suppl. III) 1983; 38 (Abst)
    CrossrefPubMedGoogle Scholar
  • 39 Lew AS, Neer T, Rodriquez L, Geft IL, Shah PK, Ganz W. Clinical failure of streptokinase due to an unsuspected high titer of antistreptokinsae antibody. J Am Coll Cardiol 1: 183-185 1984;
    PubMedGoogle Scholar
  • 40 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 32: 427-436 1983;
    CrossrefPubMedGoogle Scholar
  • 41 Collen D. Mechanisms of inhibition of tissue-type plasminogen activator in blood. Thromb Haemostas 50: 678 1983;
    PubMedGoogle Scholar
  • 42 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 46: 658-661 1981;
    PubMedGoogle Scholar
  • 43 Matsuo O. Turnover of tissue plasminogen activator in man. (Letter.). Thromb Haemostas 48: 242 1982;
    PubMedGoogle Scholar